OncLive
OncLive SOSS

Most Recent

FDA Grants Pedmark Priority Review for Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

August 7th 2020

By Kristi Rosa

The FDA has granted a priority review designation to a new drug application for a unique formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.

Longer Follow-Up Data Confirms Cemiplimab’s Utility in CSCC, Though Challenges Remain

August 7th 2020

By Jessica Hergert

Anna C. Pavlick, DO, discusses the benefit of cemiplimab for patients with cutaneous squamous cell carcinoma (CSCC), the impact of these longer follow-up data, rare, but notable, toxicities that can arise with the agent, and ongoing research efforts aimed at increasing responses to immunotherapy in the CSCC space.

Interim REFLECT Analysis Reconfirms Efficacy, Safety of Rituximab Biosimilar in DLBCL

August 7th 2020

By Erica DiNapoli

Manfred Welslau, MD, discusses findings from the REFLECT interim analysis that reconfirmed the activity of the rituximab biosimilar SDZ-RTX, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with diffuse large B-cell lymphoma.

Refining Risk-Adapted Therapy in ER+ Breast Cancer

August 7th 2020

By Caroline Seymour

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the risk of late recurrence in early breast cancer, current approaches to extended adjuvant endocrine therapy, and ongoing research evaluating assays aimed at capturing both the risk of late recurrence and benefit from extended endocrine therapy.

FDA Approves Guardant360 CDx Liquid Biopsy for Comprehensive Genomic Profiling Across All Solid Cancers

August 7th 2020

By Kristi Rosa

The FDA has approved Guardant360® CDx for comprehensive genomic profiling in patients with any solid malignant cancer.

Latest Videos

Dr. Burris on Predictive Biomarkers for Chemoimmunotherapy in TNBC
Dr. Burris on Predictive Biomarkers for Chemoimmunotherapy in TNBC
Initial Work-up for Chronic Lymphocytic Leukemia
Initial Work-up for Chronic Lymphocytic Leukemia
Dr. Chiang on the Rationale for Chemoimmunotherapy in Lung Cancer
Dr. Chiang on the Rationale for Chemoimmunotherapy in Lung Cancer
Current Management of Oncogene-Driven NSCLC
Current Management of Oncogene-Driven NSCLC
Updates in Ovarian Cancer: Frontline Maintenance
Updates in Ovarian Cancer: Frontline Maintenance
Dr. Atlas on the Rationale for Cemiplimab in Locally Advanced CSCC
Dr. Atlas on the Rationale for Cemiplimab in Locally Advanced CSCC
Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL
Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL
Dr. Trent on the Role of ctDNA in Soft Tissue Sarcoma
Dr. Trent on the Role of ctDNA in Soft Tissue Sarcoma
Dr. Hoffman on the Design of an Ongoing Trial Testing PTG-300 in Polycythemia Vera
Dr. Hoffman on the Design of an Ongoing Trial Testing PTG-300 in Polycythemia Vera
Dr. Choueiri on the Impact of the COVID-19 Pandemic on Treatment in RCC
Dr. Choueiri on the Impact of the COVID-19 Pandemic on Treatment in RCC
Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast Cancer
Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast Cancer
Dr. Kelly on Window-of-Opportunity Monotherapy Trials in Lung Cancer
Dr. Kelly on Window-of-Opportunity Monotherapy Trials in Lung Cancer
Dr. Raje on Efficacy With Melflufen in Triple-Refractory Myeloma
Dr. Raje on Efficacy With Melflufen in Triple-Refractory Myeloma
Dr. Ahmed on Remaining Questions With Tucatinib in Breast Cancer Brain Metastases
Dr. Ahmed on Remaining Questions With Tucatinib in Breast Cancer Brain Metastases
Dr. Abid on Challenges With CAR T-Cell Therapy During the COVID-19 Pandemic
Dr. Abid on Challenges With CAR T-Cell Therapy During the COVID-19 Pandemic
Dr. Costa on Unmet Needs in Relapsed/Refractory Multiple Myeloma
Dr. Costa on Unmet Needs in Relapsed/Refractory Multiple Myeloma
Dr. Schwartz on Results From the GIST Cohort in the Alliance A091401 Trial
Dr. Schwartz on Results From the GIST Cohort in the Alliance A091401 Trial
Dr. Czerniecki on the Benefit of Tucatinib in HER2+ Breast Cancer and Brain Metastases
Dr. Czerniecki on the Benefit of Tucatinib in HER2+ Breast Cancer and Brain Metastases
Dr. Jonasch on Next Steps With MK-6482 in Von Hippel-Lindau Disease–Associated RCC
Dr. Jonasch on Next Steps With MK-6482 in Von Hippel-Lindau Disease–Associated RCC
Dr. Mascarenhas on Approved and Emerging Treatment Options in Myelofibrosis
Dr. Mascarenhas on Approved and Emerging Treatment Options in Myelofibrosis
Dr. Lonial on the FDA Approval of Belantamab Mafodotin-blmf in Multiple Myeloma
Dr. Lonial on the FDA Approval of Belantamab Mafodotin-blmf in Multiple Myeloma
Dr. Roland on the Safety of Neoadjuvant Checkpoint Blockade in Sarcoma
Dr. Roland on the Safety of Neoadjuvant Checkpoint Blockade in Sarcoma
Dr. Blank on Predictive Biomarkers in Macroscopic Stage III Melanoma
Dr. Blank on Predictive Biomarkers in Macroscopic Stage III Melanoma

Featured Content

All Content

Thoracic Leaders Examine Novel Treatment Options in Mesothelioma

August 7th 2020

By Jessica Hergert

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in mesothelioma.

Multidisciplinary Collaboration Needed to Provide Cohesive Care in Advanced NSCLC

August 7th 2020

By Brittany Cote

David R. Spigel, MD, discusses the Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC initiative, analyzes the survey data, and next steps for the research.

CD30-Targeted CAR T-Cell Therapy Elicits Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

August 6th 2020

By Kristi Rosa

A CD30-targeted CAR T-cell therapy was found to elicit a high rate of durable complete responses (CRs) in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

Study Explores Genomics of Race in Prostate Cancer

August 6th 2020

By Nichole Tucker

Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.

PI3K Inhibitors and Oral Taxanes for Metastatic Breast Cancer: Where Do They Fit In?

August 6th 2020

By Christina T. Loguidice

A panel of experts in breast cancer discuss the emergence of alpelisib, review data from the BYLieve trial, discuss the role of everolimus, and review the emergence of oral taxanes.

FDA Clears First MRD Assay for Chronic Lymphocytic Leukemia

August 6th 2020

By Kristi Rosa

The FDA has cleared the clonoSEQ® assay to identify and monitor minimal residual disease in blood or bone marrow from patients with chronic lymphocytic leukemia.

Dizon Discusses Elements of Sexual Health in Gynecologic Cancer

August 6th 2020

By OncLive Staff

In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.

FDA Approval Sought for Omburtamab in Pediatric Metastatic Neuroblastoma

August 6th 2020

By Kristi Rosa

The biologics license application for the investigational B7-H3–targeting monoclonal antibody omburtamab for use in pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been submitted to the FDA under the agency’s Rolling Review process.

Rapid Progress Made With Late-Line Therapies in Metastatic Urothelial Cancer

August 6th 2020

By Erica DiNapoli

Praful K. Ravi, MD, discusses the emergence of immunotherapies, FGFR inhibitors, and antibody-drug conjugates and how they dramatically evolved the metastatic urothelial cancer treatment paradigm.

COVID-19 Spurs New Frameworks for Surgical Management of GU Cancers

August 6th 2020

By Jessica Hergert

Steven Lee Chang, MD, MS, discusses the impact of the COVID-19 pandemic on surgical practices, alternative options to surgery, and potential lessons to be learned from the pandemic.

x